CL2020002187A1 - Compuestos de 4 - metildihidropirimidinona y su uso farmacéutico. - Google Patents

Compuestos de 4 - metildihidropirimidinona y su uso farmacéutico.

Info

Publication number
CL2020002187A1
CL2020002187A1 CL2020002187A CL2020002187A CL2020002187A1 CL 2020002187 A1 CL2020002187 A1 CL 2020002187A1 CL 2020002187 A CL2020002187 A CL 2020002187A CL 2020002187 A CL2020002187 A CL 2020002187A CL 2020002187 A1 CL2020002187 A1 CL 2020002187A1
Authority
CL
Chile
Prior art keywords
methyldihydropyrimidinone
compounds
pharmaceutical use
pharmaceutical
pharmaceutically acceptable
Prior art date
Application number
CL2020002187A
Other languages
English (en)
Inventor
Taku Ikenogami
Takayuki Sakai
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of CL2020002187A1 publication Critical patent/CL2020002187A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente se refiere a compuestos de 4–metildihidropirimidinona o sus sales farmacéuticamente aceptables, que tienen actividad antagonista de RORγ, composiciones farmacéuticas que los comprenden y su uso farmacéutico. Se proporcionan un compuesto de la fórmula (1) o (2) o una de sus sales farmacéuticamente aceptables, una composición farmacéutica que lo comprende y su uso farmacéutico.
CL2020002187A 2018-02-28 2020-08-25 Compuestos de 4 - metildihidropirimidinona y su uso farmacéutico. CL2020002187A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2018035597 2018-02-28

Publications (1)

Publication Number Publication Date
CL2020002187A1 true CL2020002187A1 (es) 2020-12-18

Family

ID=67805061

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020002187A CL2020002187A1 (es) 2018-02-28 2020-08-25 Compuestos de 4 - metildihidropirimidinona y su uso farmacéutico.

Country Status (19)

Country Link
US (2) US10899717B2 (es)
EP (1) EP3760616A4 (es)
JP (1) JP7282546B2 (es)
KR (1) KR20200126973A (es)
CN (1) CN111741947B (es)
AR (1) AR114270A1 (es)
AU (1) AU2019228915A1 (es)
BR (1) BR112020016785A2 (es)
CA (1) CA3087994A1 (es)
CL (1) CL2020002187A1 (es)
CO (1) CO2020011860A2 (es)
IL (1) IL276323A (es)
MX (1) MX2020008982A (es)
PE (1) PE20210550A1 (es)
PH (1) PH12020551341A1 (es)
RU (1) RU2020131402A (es)
SG (1) SG11202007117RA (es)
TW (1) TW202000650A (es)
WO (1) WO2019167981A1 (es)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11912715B2 (en) 2016-08-29 2024-02-27 Novartis Ag Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections
US12071441B2 (en) 2018-02-28 2024-08-27 Novartis Ag 10-(di(phenyl)methyl)-4-hydroxy-8,9,9A,10-tetrahydro-7H-pyrrolo[1′,2′:4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021149786A1 (en) 2020-01-24 2021-07-29 Japan Tobacco Inc. Methods of treating cancer using dihydropyrimidin-2-one compounds
WO2023232870A1 (en) 2022-05-31 2023-12-07 Immunic Ag Rorg/rorgt modulators for the treatment of virus infections like covid-19

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4485107A (en) 1982-11-01 1984-11-27 Janssen Pharmaceutica N.V. [[Bis(aryl)methylene]-1-piperidinyl]alkyl-pyrimidinones
AU2006327181A1 (en) 2005-12-22 2007-06-28 Hydra Biosciences, Inc. TRPA1 inhibitors for treating pain
US20100010024A1 (en) 2006-07-01 2010-01-14 Bayer Healthcare Ag Use of1,4-diaryl-dihydropyrimidine-2-on derivatives for treating pulmonary arterial hypertension
DE102006031314A1 (de) 2006-07-01 2008-01-03 Bayer Healthcare Aktiengesellschaft Verwendung von 1,4-Diaryl-dihydropyrimidin-2-on-Derivaten zur Behandlung der pulmonalen arteriellen Hyptertonie
US20110201634A1 (en) 2008-06-13 2011-08-18 Delhi University Dihydropyridimidinone compounds for the treatment of cardiovascular diseases and process for preparing the same
WO2011115892A1 (en) * 2010-03-15 2011-09-22 Griffin Patrick R Modulators of the retinoic acid receptor-related orphan receptors
EP2927217B1 (en) 2011-04-28 2018-01-17 Japan Tobacco Inc. Amide compound and pharmaceutical application therefor
EP2682389A1 (en) 2012-07-02 2014-01-08 Commissariat A L'energie Atomique Et Aux Energies Alternatives Dihydropyrimidin-2(1H)-ones and dihydropyrimidin-2(1H)-thiones as inhibitors of sodium iodide symporter
JO3215B1 (ar) 2012-08-09 2018-03-08 Phenex Pharmaceuticals Ag حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy
WO2014062938A1 (en) 2012-10-19 2014-04-24 Bristol-Myers Squibb Company Rory modulators
US20160137639A1 (en) 2012-10-26 2016-05-19 Japan Tobacco Inc. Triazole-isoxazole compound and medical use thereof
CN103113308B (zh) 2013-01-25 2014-11-19 浙江大学 一种制备二氢嘧啶酮衍生物的方法
US9809561B2 (en) * 2013-12-20 2017-11-07 Merck Sharp & Dohme Corp. Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease
BR112017012504A2 (pt) 2014-12-12 2018-01-09 Acetylon Pharmaceuticals, Inc. derivados de piperidina como inibidores de hdac1/2
KR102551018B1 (ko) * 2014-12-12 2023-07-05 니뽄 다바코 산교 가부시키가이샤 디히드로피리미딘-2-온 화합물 및 그의 의약 용도
TW201630881A (zh) 2014-12-12 2016-09-01 Ｈ 朗德貝克公司 用於生產艾達魯吡啶之方法
CN106999493A (zh) 2014-12-12 2017-08-01 默克专利股份公司 具有抗癌活性的6‑氧代‑1,6‑二氢‑哒嗪衍生物与egfr抑制剂的组合
US11358967B2 (en) * 2016-01-20 2022-06-14 Boehringer Ingelheim International Gmbh Substituted pyrazino[2,3-b]pyrazines and pyrazino[2,3-c]pyridazines as modulators of ROR gamma

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11912715B2 (en) 2016-08-29 2024-02-27 Novartis Ag Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections
US12071441B2 (en) 2018-02-28 2024-08-27 Novartis Ag 10-(di(phenyl)methyl)-4-hydroxy-8,9,9A,10-tetrahydro-7H-pyrrolo[1′,2′:4,5]pyrazino[1,2-b]pyridazine-3,5-dione derivatives and related compounds as inhibitors of the orthomyxovirus replication for treating influenza

Also Published As

Publication number Publication date
JP7282546B2 (ja) 2023-05-29
IL276323A (en) 2020-09-30
SG11202007117RA (en) 2020-08-28
CN111741947A (zh) 2020-10-02
US20210363110A1 (en) 2021-11-25
TW202000650A (zh) 2020-01-01
EP3760616A1 (en) 2021-01-06
BR112020016785A2 (pt) 2021-02-09
CA3087994A1 (en) 2019-09-06
PH12020551341A1 (en) 2021-06-21
US10899717B2 (en) 2021-01-26
RU2020131402A (ru) 2022-03-24
PE20210550A1 (es) 2021-03-17
WO2019167981A1 (ja) 2019-09-06
JP2019151623A (ja) 2019-09-12
KR20200126973A (ko) 2020-11-09
AU2019228915A1 (en) 2020-07-02
CO2020011860A2 (es) 2021-01-18
EP3760616A4 (en) 2021-11-03
MX2020008982A (es) 2020-09-28
CN111741947B (zh) 2024-06-11
AR114270A1 (es) 2020-08-12
US20190300488A1 (en) 2019-10-03

Similar Documents

Publication Publication Date Title
CO2020011860A2 (es) Compuestos de 4–metildihidropirimidinona y su uso farmacéutico
CO2020016285A2 (es) Compuestos heterocíclicos y de heteroarilo para tratar la enfermedad de huntington
CL2020001218A1 (es) Compuestos útiles para inhibir a cdk7.
SA521422143B1 (ar) 15-pgdh مثبط
MX2020005063A (es) Inhibidores de kras g12c.
AR107864A1 (es) ÁCIDO 7a,11b-DIHIDROXI-6a-ETIL-5b-COLAN-24-OICO Y COMPOSICIONES FARMACÉUTICAS
UY38186A (es) Sal sódica de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-1-isopropil-1h-pirazol-3-sulfonamida
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
MX2021013854A (es) Compuestos para tratar enfermedad de huntington.
CL2018003291A1 (es) Amidas heterocíclicas útiles como moduladores de proteínas (divisional de solicitud cl 2850-2018).
ECSP19051352A (es) Inhibidores selectivos de jak1
MX386103B (es) Inhibidores de mcl-1 y metodos de uso de los mismos.
MX381041B (es) Compuesto cíclico tipo cumarina como inhibidor de mek y su uso.
JOP20180113A1 (ar) مركبات ,تركيبات وطرق
MX2022001789A (es) Derivados de 2-hidroxicicloalcan-1-carbamoilo.
CL2021001396A1 (es) Derivados de panteteína y usos de los mismos
EA201990388A1 (ru) Пиперидиновые модуляторы рецепторов cxcr7
PY1923494A (es) Derivados de n-(3-(7h-pirrolo[2,3-d]pirimidin-4-il)fenil)benzamida
CL2020002188A1 (es) Compuestos de dihidropirimidinona o dihidrotriazinona fusionados con anillos saturados y su uso farmacéutico.
BR112017020081A2 (pt) análogos deuterados de etifoxina, seus derivados e usos dos mesmos
CU20190029A7 (es) Compuestos de aza-indazol útiles en lesiones de tendones y/o ligamentos
CO2018001700A2 (es) Derivados de n-[1h-bencimidazol-2-il] metil-pirazin-2-il-carboxamida, composiciones y procedimientos de preparación de los mismos
SA521421354B1 (ar) مركبات مفيدة في صورة مُعدِّلات الالتهام الذاتي الذي تتوسط فيه شابرون
MX2022003504A (es) Inhibidor de irak y metodo de preparacion para el mismo y uso del mismo.